Suspended NA INTERVENTIONAL NCT00695032

Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors

Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT)

Sponsor: Institut Claudius Regaud

Conditions Chemotherapeutic Agent Toxicity Renal Toxicity Unspecified Adult Solid Tumor, Protocol Specific

Interventions cisplatin ifosfamide laboratory biomarker analysis

Updated 5 times since 2017 Last updated: Nov 4, 2014 Started: Oct 31, 2007 Primary completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

This trial was suspended. No reason was provided.

A NA clinical study on Chemotherapeutic Agent Toxicity and Renal Toxicity, this trial is suspended. The trial is conducted by Institut Claudius Regaud and has accumulated 5 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Suspended NA
Jul 2024 — Sep 2024 [monthly]

Suspended NA
Jan 2021 — Jul 2024 [monthly]

Suspended NA
Jun 2018 — Jan 2021 [monthly]

Suspended NA
Jan 2017 — Jun 2018 [monthly]

Suspended NA

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Claudius Regaud

Data source: Institut Claudius Regaud

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toulouse, France